



## List of Figures

Figure No.	Title	Page
Figure 2.1	Possible pathways for dermal delivery of drug	4
Figure 2.1	Anatomy of Skin	13
Figure 2.2	A schematic representation of the skin and the way various enhancement strategies	16
Figure 2.3	Various techniques of optimizing transdermal drug delivery	20
Figure 2.4	O/W type, W/O type and bicontinuous microemulsion	27
Figure 2.5	Different regions of phase diagram	35
Figure 2.6	Ternary system	35
Figure 2.7	Immunological pathways in atopic dermatitis	49
Figure 2.8	Mechanism of action of topical corticosteroids	60
Figure 2.9	Methods for BA/BE testing of topical glucocorticoids	65
Figure 2.10	Mechanism of action of topical calcineurin inhibitors	69
Figure 3.1	UV spectra of halobetasol propionate (5-45 mcg/ml) in methanol	113
Figure 3.2	Calibration curve of halobetasol propionate in methanol at 239nm	113
Figure 3.3	Visible spectra of halobetasol propionate (2.5-12.5 mcg/ml) by tetrazolium blue colormetric method	116
Figure 3.4	Calibration plot of halobetasol propionate by tetrazaolium blue method (525 nm)	116
Figure 3.5	Chromatogram of halobetasol propionate 10 mcg/ml	118
Figure 3.6	Calibration curve of halobetasol propionate by HPLC at 239 nm	118
Figure 3.7	Chromatograms of tacrolimus	120
Figure 3.8	Calibration curve of tacrolimus by HPLC at 210 nm	120
Figure 3.9	Chromatogram of tacrolimus (50 mcg/ml)	121
Figure 3.10	Calibration curve of tacrolimus by HPLC at 210 nm	122
Figure 3.11	Calibration plot of serum IgE levels in mice by ELISA	123
Figure 4.1	Phase diagram of HP system 1	140
Figure 4.2	Phase diagram of HP system 2	140
Figure 4.3	Phase diagram of HP system 3	141
Figure 4.4	Contour plot for zeta potential of HP system1	143
Figure 4.5	Contour plots for globule size of HP system 1	143
Figure 4.6	Contour plot for zeta potential of HP system2	146
Figure 4.7	Contour plot for globule size of HP system2	146

Figure 4.8	Contour plot for zeta potential of HP system 3	149
Figure 4.9	Contour plot for globule size of HP system 3	149
Figure 4.10	Zeta potential distribution of the optimized batch A14	151
Figure 4.11	Size distribution of the optimized batch A14	151
Figure 4.12	Phase diagram of Tac system 1	152
Figure 4.13	Phase diagram of Tac system 2	152
Figure 4.14	Phase diagram of Tac system 3	153
Figure 4.15	Contour plot for zeta potential of Tac system1	155
Figure 4.16	Contour plot for globule size of Tac system1	155
Figure 4.17	Contour plot for zeta potential of Tac system2	158
Figure 4.18	Contour plot for globule size of Tac system2	158
Figure 4.19	Contour plot for zeta potential of Tac system3	161
Figure 4.20	Contour plot for globule size of Tac system3	161
Figure 4.21	Zeta potential distribution of the optimized batch D12	163
Figure 4.22	Size distribution of the optimized batch D12	163
Figure 4.23	Transmission electron microscopic image of HP ME	164
Figure 4.24	Transmission electron microscopic image of Tac ME	164
Figure 4.25	TEM image of cetomacrogol cream base after negative staining with phosphotungstic acid	165
Figure 4.26	TEM image of cetomacrogol cream base after incorporation of HP ME and negative staining with phosphotungstic acid.	165
Figure 4.27	TEM image of cetomacrogol cream base after incorporation of Tac ME and negative staining with phosphotungstic acid.	166
Figure 5.1	A two compartment diffusion cell	183
Figure 5.2	Comparative cumulative HP release through semi permeable cellulose acetate membrane	193
Figure 5.3	Comparative HP retention in rat skin and human cadaver skin following 24 h application	193
Figure 5.4	Comparative cumulative Tac release through semi permeable cellulose acetate membrane	196
Figure 5.5	Comparative Tac retention in rat skin and human cadaver skin following 24 h application	196
Figure 6.1	HE staining of rat biopsy for placebo group	214
Figure 6.2	Toluidine Blue staining of rat biopsy for placebo group	214
Figure 6.3	HE staining of rat skin biopsy for HPMEC0.035% group	215
Figure 6.4	Toluidine Blue staining of rat skin biopsy for HPMEC.0.035% group.	215

Figure 6.5	HE staining of rat skin biopsy for HPMEC 0.05% group	216
Figure 6.6	Toluidine Blue staining of rat skin biopsy for HPMEC 0.05% group.	216
Figure 6.7	HE staining of rat skin biopsy for TacMEC 0.1% group	217
Figure 6.8	Toluidine Blue staining of rat skin biopsy for TacMEC 0.1% group	217
Figure 6.9	Irritation score in human subjects over a period of 48 hours	219
Figure 7.1	Conversion from a Th1- (left) to a Th2-dominated (right) response upon repeated hapten application in a hapten-induced mouse model	226
Figure 7.2	Penetration of 6-coumarin into mice abdominal skin from HP cream	233
Figure 7.3	Penetration of 6-coumarin into mice abdominal skin from HP ointment	233
Figure 7.4	Penetration of 6-coumarin into mice abdominal skin from HPMEC	233
Figure 7.5	Comparative dermatitis score in mice during the course of study after elicitation with inducing agent (TNCB) and treatment with different formulations	234
Figure 7.6	Ear swelling response in mice recorded 3 h post application of formulations	236
Figure 7.7	Ear swelling response in mice recorded 24 h post application of formulations	236
Figure 7.8	Comparative serum total IgE levels during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different HP formulations	239
Figure 7.9	Histopathology of ear skin lesions caused by repeated application of TNCB and after treatment with HP formulations in BALB/C mice	241
Figure 7.10	Mast cell numbers during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different formulations	243
Figure 7.11	Gel electrophoresis of total RNA extracted from mice ear	243
Figure 7.12	Cytokine mRNA expression in the skin lesion excised 24 h after elicitation with TNCB painting	244
Figure 7.13	Cytokine gene expression by RT-PCR at the end of study on day 35	244

Figure 7.14	Penetration of 6-coumarin into mice abdominal skin from Tac ointment	246
Figure 7.15	Penetration of 6-coumarin into mice abdominal skin from Tac MEC	246
Figure 7.16	Comparative dermatitis score in mice during the course of study after elicitation with inducing agent (TNCB) and treatment with different Tac formulations	247
Figure 7.17	Comparative serum total IgE levels during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different Tac formulations	248
Figure 7.18	Ear swelling response in mice recorded 3 h post application of formulations	249
Figure 7.19	Ear swelling response in mice recorded 24 h post application of formulations	250
Figure 7.20	Mast cell numbers during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different Tac formulations	251
Figure 7.21	Histopathology of ear skin lesions caused by repeated application of TNCB and treatment with different Tac formulations in BALB/C mice	253
Figure 7.22	Cytokine mRNA expression in the skin lesion excised 24 h after elicitation with TNCB painting	253
Figure 7.23	Cytokine gene expression levels by RT -PCR at the end of study on day 35.	255
Figure 8.1	Skin blanching curve for HP cream 0.05% and HPMEC 0.035% after 2 h of application	286
Figure 8.2	Skin blanching curve for HP cream 0.05% and HPMEC 0.035% after 4 h of application	287
Figure 8.3	Skin blanching curve for HP cream 0.05% and HPMEC 0.035% after 6 h of application	288
Figure 8.4	Comparative percentage reduction in signs and symptoms at the end of treatment for HPMEC 0.035% and HP cream 0.05%	292
Figure 8.5	Comparative percentage reduction in signs and symptoms at the end of treatment for HPMEC 0.035% and MEC placebo	292
Figure 8.6	Comparative percentage reduction in signs and symptoms at the end of treatment for HP cream 0.05% and Cream Placebo	293

Figure 8.7	Comparative percentage reduction in signs and symptoms at the end of treatment for MEC Placebo and Cream Placebo	293
Figure 8.8	Comparative overview of patient & physician global assessment for group1: HPMEC 0.035% and group2: HP Cream 0.05%	294
Figure 9.1	Chromatogram of HP at 239 nm	306
Figure 9.2	Chromatogram of Tac at 210 nm	306
Figure 9.3	DSC thermograms a) Tacrolimus b) Halobetasol propionate	308
Figure 9.4	DSC thermograms a) Tac + HP mix at time 0. b) Tac + HP mix at time :1 month	308
Figure 9.5	Comparative cumulative drug release through semi permeable cellulose acetate membrane	310
Figure 9.6	Comparative drug retention in rat skin and human cadaver skin following 24 h application	311
Figure 9.7	Comparative dermatitis score in mice during the course of study after elicitation with inducing agent (TNCB) and treatment with different formulations	312
Figure 9.8	Comparative serum total IgE levels during the course of study after sensitization and elicitation with hapten (TNCB) and treatment with different formulations.	313
Figure 9.9	Ear swelling response in mice recorded 3 h post application of formulations	314
Figure 9.10	Ear swelling response in mice recorded 24 h post application of formulations	315
Figure 9.11	Histopathology of ear skin lesions caused by repeated application of TNCB and after treatment with formulations in BALB/C mice	316
Figure 9.12	Cytokine gene expression levels by RT -PCR at the end of study on day 35	319